Robert Bruce Montgomery, MDDr. Bruce Montgomery is clinical director of genitourinary medical oncology, carrying out research and seeing men and women with genitourinary cancers at SCCA/UWMC.
Patient Care Philosophy:
We want to provide the best care, all the time, for every patient. The Urologic Oncology clinics at SCCA are designed to provide a multidisciplinary team approach, while offering treatment tailored to each person, according to their needs and optimizing the quality of life.
Dr. Montgomery's Resume
- Associate Professor, Medical Oncology Division, University of Washington School of Medicine
- Affiliate Member, Clinical Research Division, Fred Hutchinson Cancer Research Center
- Medical Oncologist, Seattle Cancer Care Alliance
- Treatment of high risk and advanced prostate cancer
- Treatment of bladder and testicular cancer
- Drug resistance to hormonal therapy and taxane chemotherapy
Education And Training
- Duke University School of Medicine, 1987
- Residency: Brigham and Women's Hospital Internal Medicine, 1988-1990
- Fellowship: University of Washington Medical Oncology, 1990-1993
- Dr. Montgomery was recognized as a 2013 "Top Doctor" in Seattle Met magazine's annual survey.
- Molecular correlates of sensitivity and resistance to therapy in prostate cancer (UW6932)
- Abiraterone Acetate for Metastatic, Castration Resistant Prostate Cancer
- Degarelix Acetate Prior to Radiation Therapy (7846)
- Abiraterone Acetate for Metastatic Hormone-Resistant Prostate Cancer (7639)
- Abiraterone With Or Without ABT-888 For Metastatic Castration-Resistant Prostate Cancer (7847)
- CFG920 for Castration Resistant Prostate Cancer
- Oral CFG920 for Castration Resistant Prostate Cancer
- Galeterone for Castration Resistant Prostate Cancer (ARMOR2)
- Sirolimus + Cisplatin/Gemcitabine for Bladder Cancer (8027)
Dr. Montgomery's Story
Dr. Bruce Montgomery made the switch from laboratory research to patient care and clinical research because he wanted to work with the prostate cancer team at UW Medicine and Seattle Cancer Care Alliance.
“It was the opportunity to work with my colleagues in medical oncology, urology and radiation oncology as well as the rest of the Program in Prostate Cancer Research, that first attracted me to doing research in prostate cancer and ultimately to doing clinical trials and treating patients,” says Dr. Montgomery.
He says he likes being part of the team: “It’s a great group and a remarkable team experience. We all collaborate. The group is very cohesive; they’ve found a way to really work together.”
Dr. Paul Lange, the well-known prostate surgeon and urologist who sees patients at SCCA and is chairman of the Department of Urology at the University of Washington, talks about why he wanted Dr. Montgomery to join the team: “Bruce brings a wealth of experience not only in medical oncology but also in basic cancer research to our table. Until we were able to lure him to UW/SCCA and our prostate pavilion clinic, he was very involved in basic research and in the treatment of GU—and other cancers—at the VA, where he was one of the major players in medical oncology.”
Dr. Montgomery divides his time between seeing patients at the SCCA Prostate Center and research. He is a medical oncologist, an associate professor at UW Medicine, one of SCCA’s parent organizations, and an affiliate member of the Clinical Research Division of Fred Hutchinson Cancer Research Center, another SCCA founding organization.
“Bruce is a very compassionate, conscientious, and skillful physician, a real intellectual when it comes to cancer knowledge, and an outstanding researcher who is now devoting a majority of his research time to clinical trials.”
Dr. Montgomery and his colleagues are researching new ways of making prostate cancer cells more sensitive to chemotherapy and hormonal therapy. Dr. Montgomery is a medical oncologist who generally sees men with prostate, bladder and testicular cancer, which may be treated with chemotherapy or other options such as hormone therapy.
Until recently, men with early stage prostate cancer were treated only with surgery or radiation, but Dr. Montgomery says that this is starting to change. “Oncologists are beginning to use chemotherapy and vaccines to treat men with earlier-state prostate cancer if their disease has certain high-risk features, such as a very high PSA or high Gleason scores. For these men, the chance of a recurrence is high, perhaps 50 percent or higher.”
These new treatments for high-risk prostate cancer are being evaluated in a number of clinical trials, and Dr. Montgomery often finds himself discussing the pros and cons of enrolling in clinical research with his patients.
He acknowledges that enrolling in a clinical trial can be a scary proposition, but says that he will often ask a patient to join a study both because he is hoping to help that patient and because he is looking to the future, hoping to improve the treatments available for prostate cancer.
“We are going in with the hope that the trial will have benefit for you and also for the next man down the road who has to deal with the disease,” he says. “I tell my patients, we wouldn’t have the standard of care we have now without other men who joined in this collaboration between patients and researchers.”